Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabwell Starts Trials of mAb to Regulate Iron Homeostasis In Vivo

publication date: Mar 15, 2023

Shanghai Mabwell has started a Phase I trial of 9MW301, the company’s iron homeostasis regulating macromolecular drug. The candidate is a mAb with an innovative target that Maxwell developed at its San Diego Innovation and R&D Center. In China, the mAb is a Category 1 Therapeutic Biological Product. 9MW3011 has been approved to begin trials in China and the US for two rare disease indications: β-thalassemia and polycythemia vera. In January 2023, Mabwell out-licensed global rights (ex-China) for the drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. More details....

Stock Symbol: (SHA: 688062)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China